Becton Dickinson vs. Beckman Coulter: Fluorescent Dye Patent Dispute Ends in Mutual Dismissal
Was möchten Sie als Nächstes tun?
Wählen Sie Ihren Weg entsprechend Ihren aktuellen Bedürfnissen:
📋 Fallzusammenfassung
| Fallbezeichnung | Becton, Dickinson and Company v. Beckman Coulter, Inc. |
| Fallnummer | 3:21-cv-01173 (S.D. Cal.) |
| Gericht | US-Bezirksgericht für den südlichen Bezirk von Kalifornien |
| Dauer | June 2021 – July 2024 3 years |
| Ergebnis | Mutual Dismissal With Prejudice |
| Legal Reps | Plaintiffs: Barbara A. Fiacco (Foley Hoag LLP) Defendant: David M. Krinsky (Williams & Connolly LLP) |
| Streitige Patente | |
| Beschuldigte Produkte | Beckman Coulter’s SuperNova Dyes and corresponding dye-antibody conjugates |
Fallübersicht
Die Parteien
⚖️ Kläger
A global medical technology leader with extensive IP holdings in diagnostics and life sciences instrumentation. Co-plaintiffs Sirigen, Inc. and Sirigen II Limited are BD subsidiaries specializing in conjugated polymer dye technologies.
🛡️ Beklagter
A Danaher Corporation subsidiary and major competitor in flow cytometry instrumentation and reagent systems. Its SuperNova Dye line directly competes with BD’s Brilliant dye products.
Streitige Patente
This case involved 13 U.S. patents covering conjugated polymer fluorescent dye technologies, foundational to modern multi-parameter flow cytometry panels. These patents collectively protect the synthesis, composition, and application of **conjugated polymer-based fluorescent dyes** and **dye-antibody conjugates**.
- • US10641775B2 | US9139869B2 | US8362193B2
- • US10302648B2 | US10288620B2 | US8455613B2
- • US9547008B2 | US10955417B2 | US8575303B2
- • US10458989B2 | US10962546B2 | US10094838B2
- • US10365285B2
Developing a new fluorescent dye or reagent?
Check if your product might infringe these or related patents before launch.
Das Urteil und die rechtliche Analyse
Ergebnis
On July 12, 2024, the parties filed a **Joint Motion and Stipulation of Dismissal** pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii). The court granted the motion, ordering plaintiffs’ claims and defendant’s counterclaims dismissed **with prejudice**, with each party bearing its own costs. No damages award was disclosed, and no injunctive relief was ordered, strongly suggesting a **confidential settlement agreement**.
Wichtige rechtliche Fragen
The litigation centered on **patent infringement** across 13 conjugated polymer dye patents. Beckman Coulter’s litigation posture likely included invalidity counterclaims, potentially challenging patents on grounds of prior art or enablement. The breadth of the patent portfolio asserted created comprehensive infringement exposure. The dismissal with prejudice of Beckman Coulter’s counterclaims precludes re-litigation of those specific challenges, a meaningful concession that may have formed part of settlement negotiations.
While the case produced no published claim construction ruling or validity determination, its significance lies in the strategic use of a broad patent portfolio for litigation leverage and the ultimate resolution through a mutual Rule 41 dismissal, which permanently extinguishes all claims and counterclaims.
Freedom-to-Operate-Analyse (FTO)
This case highlights critical IP risks in the fluorescent dye and reagent space. Choose your next step:
📋 Die Auswirkungen dieses Falls verstehen
Informieren Sie sich über die spezifischen Risiken und Auswirkungen dieses Rechtsstreits.
- View all 13 asserted patents in this technology space
- See which companies are most active in fluorescent dyes
- Understand conjugated polymer dye claim patterns
🔍 Das Risiko meines Produkts überprüfen
Führen Sie eine umfassende FTO-Analyse für Ihre eigene Technologie oder Ihr eigenes Produkt durch.
- Geben Sie Ihre Produktbeschreibung oder technischen Merkmale ein.
- KI identifiziert potenziell blockierende Patente
- Erhalten Sie einen umsetzbaren Risikobewertungsbericht
Hochrisikogebiet
Conjugated polymer dye compositions
13 geltend gemachte Patente
In fluorescent dye space
Strategische Entschließung
Via confidential settlement
✅ Wichtigste Erkenntnisse
Thirteen-patent portfolio assertions create compounding invalidity burdens for defendants and substantial settlement leverage for plaintiffs.
Verwandte Rechtsprechung suchen →Dismissal with prejudice of counterclaims extinguishes invalidity challenges permanently — a critical negotiating point in settlement discussions.
Präzedenzfälle erkunden →Rule 41(a)(1)(A)(ii) joint dismissals in complex patent cases frequently signal confidential commercial resolutions.
Understand procedural dynamics →Häufig gestellte Fragen
The case involved 13 U.S. patents (including US10641775B2, US9139869B2, US8362193B2, and ten additional patents) covering conjugated polymer fluorescent dye technologies assigned to Becton Dickinson and its Sirigen subsidiaries.
Both parties filed a joint stipulation of dismissal under FRCP Rule 41(a)(1)(A)(ii) on July 12, 2024, indicating a mutually agreed resolution. Dismissal with prejudice permanently bars re-litigation of the same claims.
The unresolved judicial record leaves BD’s 13-patent portfolio legally intact and untested by verdict, maintaining ongoing IP risk for competitors developing conjugated polymer dye technologies in the flow cytometry reagent market.
Sind Sie bereit, Ihre Patentstrategie zu stärken?
Schließen Sie sich den über 18.000 Fachleuten aus dem Bereich des geistigen Eigentums an, die PatSnap Eureka nutzen, um mit KI-gestützter Präzision Recherchen zum Stand der Technik durchzuführen, Patentanmeldungen zu erstellen und Wettbewerbslandschaften zu analysieren.
Referenzen
- PACER Case Lookup – Case No. 3:21-cv-01173
- USPTO-Patent-Volltextdatenbank
- Southern District of California Court Records
- PatSnap – Lösungen für den Umgang mit geistigem Eigentum für Anwaltskanzleien
Dieser Artikel dient ausschließlich zu Informationszwecken und stellt keine Rechtsberatung dar. Alle Angaben zu den Fällen stammen aus öffentlich zugänglichen Gerichtsakten. Informationen zu den Funktionen der Plattform finden Sie auf PatSnap.